Artwork

Konten disediakan oleh Flot.bio. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Flot.bio atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
Player FM - Aplikasi Podcast
Offline dengan aplikasi Player FM !

Gunilla Osswald, BioArctic 🇸🇪 | Leqembi, Alzheimer’s disease | E26

54:25
 
Bagikan
 

Manage episode 454616341 series 3470295
Konten disediakan oleh Flot.bio. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Flot.bio atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.

We’re at BIO-Europe in Stockholm 🇸🇪 with Gunilla Osswalld, the CEO of BioArctic, the inventor of one of the only drugs that have worked for Alzheimer's.

We talked about the science and business behind Leqembi. We also talked about the Alzheimer’s field at large and transitioning from big pharma to biotech.

— — —

Thank you to today’s sponsor, Turbine, who is organizing a free Techbio event at JPM25 and is inviting you to join. Click the link to RSVP and secure one of the limited spots:

https://www.turbine.ai/jpm25-event-registration

— — —

⭐️ ABOUT THE SPEAKER

Gunilla joined BioArctic in 2013 after many successful years in executive positions at Astra/AstraZeneca, including Vice President for the product portfolio of neurodegenerative diseases. Since joining BioArctic, the largest Swedish biotech, Leqembi, one of the only successful drugs for Alzheimer’s was approved. This was an invention of BioArctic that Eisai and Biogen have commercialized. This is a particularly impressive feat considering 98% of Alzheimer’s drugs fail.

🔗 LINKS MENTIONED-

The CEO of BioArctic talks Leqembi and what's next in Alzheimer's, Parkinson's, ALS, and more: https://www.biotechtv.com/post/bioarctic-gunilla-osswald-september-21-2024

- Roche sees rapid amyloid clearing in Alzheimer's study, adjusts protocol after patient death: https://www.fiercebiotech.com/biotech/roche-sees-rapid-amyloid-clearing-early-alzheimers-study

- Edwin Moses | How to build large biotech platforms | E13: https://flot.bio/episode/edwin-moses-biotech-platforms/

📜 TRANSCRIPT

Read the full transcript here: https://flot.bio/episode/gunilla-osswald-bioarctic-alzheimers/

💸 DONATE

We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme

⭐️ SPONSORSHIP

Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!

🫶 FOLLOW US

- Newsletter: http://eepurl.com/h_fnmH

- LinkedIn: https://www.linkedin.com/company/flot-bio/

- X (Twitter): https://x.com/FlotBio

🙏 LIKE/FOLLOW/REVIEW

Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

🎙️ ABOUT FLOT.BIO

Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free.

⏰ TIMESTAMPS

[00:00:00] Intro

[00:02:24] Leqembi and BioArctic

[00:10:40] Side effects of Leqembi for Alzheimer's treatment

[00:17:03] Passing the blood-brain barrier for better Alzheimer's treatments

[00:21:00] Market access for Leqembi in Europe

[00:27:03] Gunilla Osswald's commitment to patients

[00:31:55] Leaving AstraZeneca, transitioning to biotech

[00:38:42] Unique culture at BioArctic

[00:42:26] Alzheimer's field in Europe and at large

[00:48:20] Quickfire

[00:53:42] Thanks for listening

  continue reading

26 episode

Artwork
iconBagikan
 
Manage episode 454616341 series 3470295
Konten disediakan oleh Flot.bio. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Flot.bio atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.

We’re at BIO-Europe in Stockholm 🇸🇪 with Gunilla Osswalld, the CEO of BioArctic, the inventor of one of the only drugs that have worked for Alzheimer's.

We talked about the science and business behind Leqembi. We also talked about the Alzheimer’s field at large and transitioning from big pharma to biotech.

— — —

Thank you to today’s sponsor, Turbine, who is organizing a free Techbio event at JPM25 and is inviting you to join. Click the link to RSVP and secure one of the limited spots:

https://www.turbine.ai/jpm25-event-registration

— — —

⭐️ ABOUT THE SPEAKER

Gunilla joined BioArctic in 2013 after many successful years in executive positions at Astra/AstraZeneca, including Vice President for the product portfolio of neurodegenerative diseases. Since joining BioArctic, the largest Swedish biotech, Leqembi, one of the only successful drugs for Alzheimer’s was approved. This was an invention of BioArctic that Eisai and Biogen have commercialized. This is a particularly impressive feat considering 98% of Alzheimer’s drugs fail.

🔗 LINKS MENTIONED-

The CEO of BioArctic talks Leqembi and what's next in Alzheimer's, Parkinson's, ALS, and more: https://www.biotechtv.com/post/bioarctic-gunilla-osswald-september-21-2024

- Roche sees rapid amyloid clearing in Alzheimer's study, adjusts protocol after patient death: https://www.fiercebiotech.com/biotech/roche-sees-rapid-amyloid-clearing-early-alzheimers-study

- Edwin Moses | How to build large biotech platforms | E13: https://flot.bio/episode/edwin-moses-biotech-platforms/

📜 TRANSCRIPT

Read the full transcript here: https://flot.bio/episode/gunilla-osswald-bioarctic-alzheimers/

💸 DONATE

We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme

⭐️ SPONSORSHIP

Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!

🫶 FOLLOW US

- Newsletter: http://eepurl.com/h_fnmH

- LinkedIn: https://www.linkedin.com/company/flot-bio/

- X (Twitter): https://x.com/FlotBio

🙏 LIKE/FOLLOW/REVIEW

Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

🎙️ ABOUT FLOT.BIO

Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free.

⏰ TIMESTAMPS

[00:00:00] Intro

[00:02:24] Leqembi and BioArctic

[00:10:40] Side effects of Leqembi for Alzheimer's treatment

[00:17:03] Passing the blood-brain barrier for better Alzheimer's treatments

[00:21:00] Market access for Leqembi in Europe

[00:27:03] Gunilla Osswald's commitment to patients

[00:31:55] Leaving AstraZeneca, transitioning to biotech

[00:38:42] Unique culture at BioArctic

[00:42:26] Alzheimer's field in Europe and at large

[00:48:20] Quickfire

[00:53:42] Thanks for listening

  continue reading

26 episode

Semua episode

×
 
Loading …

Selamat datang di Player FM!

Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.

 

Panduan Referensi Cepat